Loading company…
Buffalo-based cancer immunotherapy company developing adoptive cell therapies with a dual TCR platform for solid tumors.
Founded in 2016 and headquartered in Buffalo, US, Tactiva Therapeutics develops adoptive cell therapy for solid tumors using a dual T cell receptor platform that reprograms both CD4 and CD8 T cells to recognize and attack cancer cells. The company raised USD 35 mn in Series A funding on December 3, 2018, led by Panacea Venture, with participation from Efung Capital and Virtus Inspire Ventures. Its markets are primarily North America and Europe.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in